BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sánchez-Martínez D, Lanuza PM, Gómez N, Muntasell A, Cisneros E, Moraru M, Azaceta G, Anel A, Martínez-Lostao L, Villalba M, Palomera L, Vilches C, García Marco JA, Pardo J. Activated Allogeneic NK Cells Preferentially Kill Poor Prognosis B-Cell Chronic Lymphocytic Leukemia Cells. Front Immunol 2016;7:454. [PMID: 27833611 DOI: 10.3389/fimmu.2016.00454] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
Number Citing Articles
1 Fayd'herbe De Maudave A, Leconet W, Toupet K, Constantinides M, Bossis G, de Toledo M, Vialaret J, Hirtz C, Lopez-Noriega A, Jorgensen C, Noël D, Louis-Plence P, Grizot S, Villalba M. Intra-articular delivery of full-length antibodies through the use of an in situ forming depot. J Control Release 2021;341:578-90. [PMID: 34915070 DOI: 10.1016/j.jconrel.2021.12.010] [Reference Citation Analysis]
2 Cabo M, Offringa R, Zitvogel L, Kroemer G, Muntasell A, Galluzzi L. Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications. Oncoimmunology 2017;6:e1371896. [PMID: 29209572 DOI: 10.1080/2162402X.2017.1371896] [Cited by in Crossref: 30] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]
3 Esteso G, Aguiló N, Julián E, Ashiru O, Ho MM, Martín C, Valés-Gómez M. Natural Killer Anti-Tumor Activity Can Be Achieved by In Vitro Incubation With Heat-Killed BCG. Front Immunol 2021;12:622995. [PMID: 33708215 DOI: 10.3389/fimmu.2021.622995] [Reference Citation Analysis]
4 von Wenserski L, Schultheiß C, Bolz S, Schliffke S, Simnica D, Willscher E, Gerull H, Wolters-Eisfeld G, Riecken K, Fehse B, Altfeld M, Nollau P, Binder M. SLAMF receptors negatively regulate B cell receptor signaling in chronic lymphocytic leukemia via recruitment of prohibitin-2. Leukemia 2021;35:1073-86. [PMID: 32826957 DOI: 10.1038/s41375-020-01025-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 Hofland T, Eldering E, Kater AP, Tonino SH. Engaging Cytotoxic T and NK Cells for Immunotherapy in Chronic Lymphocytic Leukemia. Int J Mol Sci 2019;20:E4315. [PMID: 31484424 DOI: 10.3390/ijms20174315] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
6 Kaur K, Cook J, Park SH, Topchyan P, Kozlowska A, Ohanian N, Fang C, Nishimura I, Jewett A. Novel Strategy to Expand Super-Charged NK Cells with Significant Potential to Lyse and Differentiate Cancer Stem Cells: Differences in NK Expansion and Function between Healthy and Cancer Patients. Front Immunol 2017;8:297. [PMID: 28424683 DOI: 10.3389/fimmu.2017.00297] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 4.2] [Reference Citation Analysis]
7 Villalba M, Alexia C, Bellin-Robert A, Fayd'herbe de Maudave A, Gitenay D. Non-Genetically Improving the Natural Cytotoxicity of Natural Killer (NK) Cells. Front Immunol 2019;10:3026. [PMID: 31998309 DOI: 10.3389/fimmu.2019.03026] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
8 Griggio V, Perutelli F, Salvetti C, Boccellato E, Boccadoro M, Vitale C, Coscia M. Immune Dysfunctions and Immune-Based Therapeutic Interventions in Chronic Lymphocytic Leukemia. Front Immunol 2020;11:594556. [PMID: 33312177 DOI: 10.3389/fimmu.2020.594556] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
9 Gonzalez-Rodriguez AP, Villa-Álvarez M, Sordo-Bahamonde C, Lorenzo-Herrero S, Gonzalez S. NK Cells in the Treatment of Hematological Malignancies. J Clin Med 2019;8:E1557. [PMID: 31569769 DOI: 10.3390/jcm8101557] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 6.0] [Reference Citation Analysis]
10 Jaime-Sánchez P, Catalán E, Uranga-Murillo I, Aguiló N, Santiago L, M Lanuza P, de Miguel D, A Arias M, Pardo J. Antigen-specific primed cytotoxic T cells eliminate tumour cells in vivo and prevent tumour development, regardless of the presence of anti-apoptotic mutations conferring drug resistance. Cell Death Differ 2018;25:1536-48. [PMID: 29743559 DOI: 10.1038/s41418-018-0112-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
11 Calvo T, Reina-Ortiz C, Giraldos D, Gascón M, Woods D, Asenjo J, Marco-Brualla J, Azaceta G, Izquierdo I, Palomera L, Sánchez-Martínez D, Marzo I, Naval J, Vilches C, Villalba M, Anel A. Expanded and activated allogeneic NK cells are cytotoxic against B-chronic lymphocytic leukemia (B-CLL) cells with sporadic cases of resistance. Sci Rep 2020;10:19398. [PMID: 33173077 DOI: 10.1038/s41598-020-76051-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
12 Wurzer H, Filali L, Hoffmann C, Krecke M, Biolato AM, Mastio J, De Wilde S, François JH, Largeot A, Berchem G, Paggetti J, Moussay E, Thomas C. Intrinsic Resistance of Chronic Lymphocytic Leukemia Cells to NK Cell-Mediated Lysis Can Be Overcome In Vitro by Pharmacological Inhibition of Cdc42-Induced Actin Cytoskeleton Remodeling. Front Immunol 2021;12:619069. [PMID: 34108958 DOI: 10.3389/fimmu.2021.619069] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Sportoletti P, De Falco F, Del Papa B, Baldoni S, Guarente V, Marra A, Dorillo E, Rompietti C, Adamo FM, Ruggeri L, Di Ianni M, Rosati E. NK Cells in Chronic Lymphocytic Leukemia and Their Therapeutic Implications. Int J Mol Sci 2021;22:6665. [PMID: 34206399 DOI: 10.3390/ijms22136665] [Reference Citation Analysis]
14 Reina-Ortiz C, Constantinides M, Fayd-Herbe-de-Maudave A, Présumey J, Hernandez J, Cartron G, Giraldos D, Díez R, Izquierdo I, Azaceta G, Palomera L, Marzo I, Naval J, Anel A, Villalba M. Expanded NK cells from umbilical cord blood and adult peripheral blood combined with daratumumab are effective against tumor cells from multiple myeloma patients. Oncoimmunology 2020;10:1853314. [PMID: 33457074 DOI: 10.1080/2162402X.2020.1853314] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
15 Sanchez-Martinez D, Allende-Vega N, Orecchioni S, Talarico G, Cornillon A, Vo DN, Rene C, Lu ZY, Krzywinska E, Anel A, Galvez EM, Pardo J, Robert B, Martineau P, Hicheri Y, Bertolini F, Cartron G, Villalba M. Expansion of allogeneic NK cells with efficient antibody-dependent cell cytotoxicity against multiple tumors. Theranostics 2018;8:3856-69. [PMID: 30083264 DOI: 10.7150/thno.25149] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
16 Vitale C, Boccellato E, Comba L, Jones R, Perutelli F, Griggio V, Coscia M. Impact of Immune Parameters and Immune Dysfunctions on the Prognosis of Patients with Chronic Lymphocytic Leukemia. Cancers (Basel) 2021;13:3856. [PMID: 34359757 DOI: 10.3390/cancers13153856] [Reference Citation Analysis]
17 Lanuza PM, Vigueras A, Olivan S, Prats AC, Costas S, Llamazares G, Sanchez-Martinez D, Ayuso JM, Fernandez L, Ochoa I, Pardo J. Activated human primary NK cells efficiently kill colorectal cancer cells in 3D spheroid cultures irrespectively of the level of PD-L1 expression. Oncoimmunology 2018;7:e1395123. [PMID: 29632716 DOI: 10.1080/2162402X.2017.1395123] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]